Current Therapeutic Strategy for Multiple Myeloma
نویسندگان
چکیده
منابع مشابه
Current therapeutic options for multiple myeloma.
or the past 25 years intermittent melphalan/prednisone has been widely used in the treatment of multiple myeloma. Several drug combinations have improved the management of refractory disease. More recently, the myeloablative approach has shown promising results. The availability of different chemotherapeutic options requires particular attention to treatment strategies applied to specific disea...
متن کاملCurrent treatment for multiple myeloma.
In the past decade, we have witnessed dramatic changes in the treatment of multiple myeloma. Proteasome inhibitors such as bortezomib and carfilzomib target the ubiquitin pathway, resulting in cytotoxic injury due to disruption of protein degradation in myeloma cells. The immunomodulatory agents thalidomide, lenalidomide, and pomalidomide target myeloma cells through several mechanisms includin...
متن کاملNewer therapeutic molecules for multiple myeloma.
Therapeutic management of multiple myeloma (MM) for the last several decades has mainly involved regimens based on use of glucocorticoids and cytotoxic chemotherapeutics. Despite progress in delineating the activity of such regimens, at either conventional or high doses, MM has remained an incurable disease. This has sparked major interest in the development of novel therapies that in part capi...
متن کاملUnderstanding novel therapeutic agents for multiple myeloma.
Multiple myeloma, a B cell malignancy of the plasma cells, remains incurable. Advances in high-dose chemotherapy and stem cell transplantation have improved overall survival and event-free disease periods, but relapses are inevitable. New therapeutic agents have shown promising clinical use in patients with relapsed or refractory multiple myeloma. This article discusses the therapeutic applicat...
متن کاملTherapeutic Advancements in Multiple Myeloma
Multiple myeloma survival has significantly improved in the latest years due to a broad spectrum of novel agents available for treatment. The introduction of thalidomide, bortezomib, and lenalidomide together with autologous stem-cell transplantation has considerably increased complete remission rate and progression-free survival resulting ultimately in prolonged survival in myeloma patients. M...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Japanese Journal of Clinical Oncology
سال: 2013
ISSN: 1465-3621,0368-2811
DOI: 10.1093/jjco/hys215